IPO Week Preview

October 20, 2026 | Week October 19–23, 2026

By Frank Whitaker With staff and AI research assistance

Research timestamp: 2026-10-21T03:58:46+00:00

Tuesday evening and the next evidence

Tuesday evening's calendar check leaves one substantial new candidate, one postponement and one unresolved trading day. That is the useful change in this October 19–23 IPO week. Lycia Therapeutics has set terms and appears on both specialist calendars. IPOScoop now marks Web3Labs Global postponed. Bitari remains a week-level candidate there, without a confirmed day. The calendar above preserves those distinctions instead of turning every proposed transaction into an appointment. [1][2][5]

The earlier picture of two small technology-related offerings no longer describes the week adequately. Lycia is seeking substantially more capital than either of them. Yet size alone tells us little about investment quality. A larger cheque can finance important research, but it also asks shareholders to accept a larger valuation before the outcome is known. The first question remains what the company will do with the money. For a small investor, there is another practical distinction: the offering price belongs to the capital-raising transaction, while the first market price reflects trading after listing. Neither is a promise that an individual can buy or sell the quantity wanted at that level.

Lycia and the work behind the offering

Lycia is based in South San Francisco and develops medicines intended to remove disease-causing proteins outside cells. Its company explanation describes LYTAC molecules that escort selected proteins into a cell's lysosome, part of its disposal machinery. Founder Carolyn Bertozzi's scientific work underpins the approach. President and chief executive Aetna Wun Trombley has led Lycia since April 2020; the company lists Amy Bachrodt as chief financial officer. [4]

The plain-English attraction is easy to understand: remove a troublesome protein rather than merely interfere with its activity. The harder question is whether that can be done safely, reliably and usefully in people. A persuasive explanation of the mechanism is the beginning of the investigation. Patients need a treatment that improves their lives, and investors need evidence that the improvement can survive larger trials and eventually support a viable business.

IPOScoop describes LCA-0061 as a Phase 1 program targeting IgE, an antibody involved in allergic disease, including food allergy. LCA-0062 is a related earlier program, while LCA-0321 is in Phase 1 for Graves' disease. Those descriptions identify research candidates, not approved products. Early changes in a biological marker should not be confused with established protection against an allergic reaction or durable control of disease. [6]

Lycia's October 20 preliminary prospectus offers 14,700,000 new shares at $16–$18, subject to change, with a proposed Nasdaq Global Select listing as LYCA. Jefferies, TD Cowen, Evercore ISI and Guggenheim Securities are joint bookrunners; LifeSci Capital is passive bookrunner. At $17, the base gross raise would be $249.9 million before fees. [3]

The same filing reports $148.1 million in cash, cash equivalents and marketable securities at June 30 and a $19.2 million first-half net loss. Collaboration revenue was zero for that half, and the Lilly agreement ended in February. The proposed capital would support pipeline development, platform work and operations. Management estimates funding into the second half of 2029 after the offering, but says more capital would be needed to reach approval. [3]

That last qualification matters more than the comforting sound of several years of runway. Runway is management's spending estimate under a plan. Trials can take longer, require more participants or produce results that change the plan. The useful comparison is between the next evidence-producing milestones and the money available to reach them. A falling accounting loss, by itself, does not establish that a research business has become self-financing.

The company announced a $75 million private financing in June, alongside changes to its finance and legal leadership. It said the funding would advance its allergy and Graves' programs toward early clinical proof of concept. That is useful history of how the research was financed; it is not evidence that the October public offering has priced or closed. [7]

Reuters reports a proposed valuation as high as $937.7 million at the range's upper end. That is an equity valuation, distinct from cash raised. Its October 20 coverage also places Lycia in a biotech window that included City and Iambic last week. Those completed earlier offerings belong in context, not in this week's calendar as fresh transactions. [8]

For competition, I would begin with the treatment a physician and patient would otherwise use, then ask what benefit Lycia must demonstrate to justify switching. A different scientific mechanism is not automatically a better patient outcome. Without a defensible comparison of effectiveness, safety and treatment burden, a neat revenue multiple from another biotech would give a false impression of precision.

Bitari still needs a date

Bitari's October 14 SEC amendment proposes 4,285,715 shares at $7 and a Nasdaq Global Market application under BIAI. The filing says listing approval was outstanding at that date. It names Chang Yao and Lawrence D. Cofield as co-chief executives. It projects 85.87% post-offering voting control through AI Power X and allocates 40% of net proceeds to acquisitions and investments without an identified acquisition target. [9]

IPOScoop describes its operating business as hosting and maintaining Bitcoin-mining equipment, with Texas sites and a contracted Indiana location. The vendor reports $11.08 million revenue and $0.46 million net income for the twelve months ended April 30, 2026. These dated measures should not be passed off as current-quarter results. [10]

My questions are practical ones: how dependable are customer payments, how much margin remains after power and service costs, and how much expansion can existing operations support? Concentrated control also means outside shareholders have limited influence over decisions. The proposed $30 million gross raise describes financing scale. It does not establish the value of the business or guarantee demand for the shares after trading begins.

Web3Labs moves to the postponed column

IPOScoop's October 20 update explicitly describes Web3Labs as postponed. Its displayed October 22 date is therefore a displaced calendar marker, not a live promise of Thursday trading. Previously proposed terms were 6.25 million shares at $4–$5, led by Eddid Securities USA. No replacement date or independently verified explanation for the postponement was established in this research. [5]

Its SEC-filed presentation describes a Hong Kong services business supporting blockchain enterprises through consulting, acceleration and marketing. Chief executive Wong Chun Long leads the company. The document reports approximately $2.202 million revenue and $882,910 net income for the year ended June 30, 2025, with weaker net income in the following six-month comparison. These are historical issuer figures, not new results accompanying the postponement. [11]

A postponement does not tell us why the timetable changed. It would be unfair to invent a financing problem, and equally careless to assume an administrative delay. The next useful update is an attributed explanation or revised offering document. Until then, the honest answer is that the deal has moved off the active schedule reported by this source.

What we know and what remains open

Lycia now has filed terms and a tentative Friday debut on IPOScoop. Bitari remains tentative without a day. Web3Labs is reported postponed. No completed October 19–23 offering was verified in the calendars checked. No separate official investor event was verified beyond the offering developments described here. The chart compares proposed base gross proceeds for the two active candidates, excluding postponed Web3Labs. [1][2]

Final prices, completed sales and opening trades remain unverified. Friday can move. The next edition should explain changes in shares, price, timing or status rather than quietly replace yesterday's assumptions. For now, the calendar has gained a substantial biotech candidate and lost an active Web3 date. That is already a story, without pretending we know how either stock will trade.

Sources

[1] IPOScoop calendar: https://www.iposcoop.com/ipo-calendar/ — retrieved 2026-10-21T03:58:46+00:00 [2] Renaissance Capital calendar: https://www.renaissancecapital.com/IPO-Center/Calendar — retrieved 2026-10-21T03:58:46+00:00 [3] Lycia October 20 SEC amendment: https://www.sec.gov/Archives/edgar/data/1806540/000162828026066381/lyciatherapeutics-sx1a.htm — retrieved 2026-10-21T03:58:46+00:00 [4] Lycia company overview and management: https://lyciatx.com/about/overview/ — retrieved 2026-10-21T03:58:46+00:00 [5] IPOScoop Web3Labs postponed profile: https://www.iposcoop.com/ipo/web3labs-global-of-hong-kong/ — retrieved 2026-10-21T03:58:46+00:00 [6] IPOScoop Lycia profile: https://www.iposcoop.com/ipo/lyca-therapeutics/ — retrieved 2026-10-21T03:58:46+00:00 [7] Lycia June financing announcement: https://www.globenewswire.com/news-release/2026/06/25/3317430/0/en/Lycia-Therapeutics-Raises-75-Million-in-Oversubscribed-Financing-and-Strengthens-Leadership-Team-with-Appointment-of-Chief-Financial-Officer-and-General-Counsel.html — retrieved 2026-10-21T03:58:46+00:00 [8] Reuters October 20 Lycia coverage: https://www.reuters.com/business/healthcare-pharmaceuticals/drug-developer-lycia-therapeutics-targets-938-million-valuation-us-ipo-2026-10-20/ — retrieved 2026-10-21T03:58:46+00:00 [9] Bitari October 14 SEC amendment: https://www.sec.gov/Archives/edgar/data/2091680/000118518526004746/bitaris1a3101326.htm — retrieved 2026-10-21T03:58:46+00:00 [10] IPOScoop Bitari profile: https://www.iposcoop.com/ipo/bitari/ — retrieved 2026-10-21T03:58:46+00:00 [11] Web3Labs SEC presentation: https://www.sec.gov/Archives/edgar/data/2091521/000121390026078199/ea0297945-fwp_web3labs.htm — retrieved 2026-10-21T03:58:46+00:00